CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV
FDA Previously Granted Rolling Review for BLA VANCOUVER, Washington, Mar 18, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential […]